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ABSTRACT Viral infection of cells is sensed by pathogen recognition receptors
that trigger an antiviral innate immune response, and consequently viruses have
evolved countermeasures. Vaccinia virus (VACV) evades the host immune re-
sponse by expressing scores of immunomodulatory proteins. One family of VACV
proteins are the BTB-BACK (broad-complex, tram-trac, and bric-a-brac [BTB] and
C-terminal Kelch [BACK]) domain-containing, Kelch-like (BBK) family of predicted
cullin-3 E3 ligase adaptors: A55, C2, and F3. Previous studies demonstrated that
gene A55R encodes a protein that is nonessential for VACV replication yet affects
viral virulence in vivo. Here, we report that A55 is an NF-B inhibitor acting
downstream of IB degradation, preventing gene transcription and cytokine se-
cretion in response to cytokine stimulation. A55 targets the host importin 1
(KPNA2), acting to reduce p65 binding and its nuclear translocation. Interest-
ingly, while A55 was conﬁrmed to coprecipitate with cullin-3 in a BTB-dependent
manner, its NF-B inhibitory activity mapped to the Kelch domain, which alone
is sufﬁcient to coprecipitate with KPNA2 and inhibit NF-B signaling. Intradermal
infection of mice with a virus lacking A55R (vΔA55) increased VACV-speciﬁc
CD8 T-cell proliferation, activation, and cytotoxicity in comparison to levels of
the wild-type (WT) virus. Furthermore, immunization with vΔA55 induced in-
creased protection to intranasal VACV challenge compared to the level with con-
trol viruses. In summary, this report describes the ﬁrst target of a poxvirus-
encoded BBK protein and a novel mechanism for DNA virus immune evasion,
resulting in increased CD8 T-cell memory and a more immunogenic vaccine.
IMPORTANCE NF-B is a critical transcription factor in the innate immune re-
sponse to infection and in shaping adaptive immunity. The identiﬁcation of host
and virus proteins that modulate the induction of immunological memory is im-
portant for improving virus-based vaccine design and efﬁcacy. In viruses, the ex-
pression of BTB-BACK Kelch-like (BBK) proteins is restricted to poxviruses and
conserved within them, indicating the importance of these proteins for these
medically important viruses. Using vaccinia virus (VACV), the smallpox vaccine,
we report that the VACV BBK protein A55 dysregulates NF-B signaling by dis-
rupting the p65-importin interaction, thus preventing NF-B translocation and
blocking NF-B-dependent gene transcription. Infection with VACV lacking A55
induces increased VACV-speciﬁc CD8 T-cell memory and better protection
against VACV challenge. Studying viral immunomodulators therefore expands not
only our understanding of viral pathogenesis and immune evasion strategies but
also of the immune signaling cascades controlling antiviral immunity and the de-
velopment of immune memory.
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Virus infection is sensed by pattern recognition receptors (PRRs) that detectpathogen-associated molecular patterns (PAMPs), and this triggers an innate im-
mune response to restrict viral replication and spread. PRR ligand binding leads to an
intracellular phosphokinase signaling cascade(s) and activation of speciﬁc inﬂammatory
transcription factors, including nuclear factor kappa-light chain-enhancer of activated B
cells (NF-B), interferon regulatory factor 3, 7, or 9 (IRF3/7/9), and signal transducer and
activator of transcription (STAT) proteins (1). Activation of these transcription factors
controls the host innate immune response by the direct and speciﬁc transcriptional
regulation of proinﬂammatory and antiviral genes. Canonical NF-B signaling mediated
via tumor necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), retinoic acid-
induced gene 1 (RIG-I)-like receptors (RLRs), and DNA sensing converges at the inhibitor
of kappa B kinase (IKK) (1). Phosphorylated IKK, in turn, phosphorylates the inhibitor
of NF-B subunit alpha (IB) that induces its cullin-1/-TrCP-dependent degradation
(2). Under normal conditions IB tethers NF-B in the cytoplasm, preventing NF-B-
dependent gene transcription. Free NF-B binds to importin 1 to 4 (karyopherin
subunit alpha 1 [KPNA1] to KPNA4)/importin  and translocates into the nucleus (3–6)
where, following phosphorylation-dependent CBP/P300 acetylation (7), it upregulates
NF-B-dependent gene transcription. NF-B-induced cytokines and chemokines then
promote inﬂammation and immune cell recruitment to clear infection.
During their evolution viruses have acquired proteins to counteract the host im-
mune response. A prototypical example is vaccinia virus (VACV), the live vaccine used
to eradicate smallpox. VACV is a member of the genus Orthopoxvirus of the Poxviridae,
a family of large double-stranded DNA viruses that replicate in the cytoplasm. To evade
the host immune response, VACV encodes a plethora of immunomodulatory proteins,
including more than 10 inhibitors of NF-B activation that function at different stages
in the pathway (8). For instance, protein B14 targets IKK to prevent IB phosphor-
ylation and degradation and subsequent p65 nuclear translocation (9). K7 was reported
to coprecipitate with TRAF6 and IRAK2 to suppress Toll-like receptor (TLR)-dependent
NF-B activation (10), and A49 blocks -TrCP-mediated degradation of phosphorylated
IB via molecular mimicry (11). Although 10 VACV inhibitors of NF-B have been
described, others exist because a virus lacking all these inhibitors still inhibited NF-B
activation (12). Ectromelia virus, a related orthopoxvirus that causes mousepox, en-
codes several inhibitors of NF-B, including the protein EVM150 (13) that shares 93%
amino acid identity with the VACV Western Reserve (WR) strain protein A55. A55
belongs to the BBK (broad-complex, tram-trac and bric-a-brac [BTB] and C-terminal
Kelch [BACK]) family of proteins (14). Interestingly, outside mammals, only poxviruses
encode Kelch-like proteins (15).
BTB-Kelch proteins are substrate-speciﬁc adaptors for the cullin-3 ubiquitin-ligase
complex and regulate modiﬁcation and/or degradation of various proteins by ubiqui-
tylation (16). Several orthopoxvirus BBK proteins coprecipitate with cullin-3 (15). The
N-terminal BTB domain is essential for cullin-3 interaction and contains a conserved
tertiary structure consisting of ﬁve -helices with A1 and A2 (A1/2) and A4/5 forming
-helical hairpins and three -strands (B1/B2/B3) forming a -sheet. The B1/B2/A1/
A2/B3 region is connected to the A4/A5 region by helix A3 and a variable linker region
(17). The Kelch motif is a segment of 44 to 56 amino acids with low overall sequence
identity, but eight key conserved residues, including four hydrophobic residues fol-
lowed by a double glycine element separated from two characteristically spaced
aromatic residues, tyrosine and tryptophan (18). Each Kelch motif represents one
-sheet blade, and several (4–7) of these repeats can form a beta-propeller (19) and a
substrate binding domain. Traditionally, the Kelch domain acts as the E3 ligase sub-
strate receptor and therefore controls substrate speciﬁcity. BBK proteins through
variation within their Kelch domains modulate a wide range of cellular processes,
including actin association/cytoskeleton organization, cell morphology, innate immu-
nity, and gene expression (18). For example, KLHL20 targets IKK to downregulate
NF-B signaling (20), while KLHL12 disrupts Wnt--catenin signaling through the
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recruitment of Dishevelled to the cullin-3 E3 ligase complex and its subsequent
ubiquitylation and degradation (21).
VACV encodes three BBK proteins, A55, C2, and F3, and one BTB-only protein, C5
(14). Like many other VACV immunomodulators, the VACV BBKs are expressed early
during infection (22) and share low amino acid identity. This is 23.5% between A55 and
F3 and 18.7% and 18.3% between C2 and A55 and F3, respectively. Previous studies
have demonstrated that the genes A55R, F3L, and C2L encode proteins that are
nonessential for virus replication yet affect virulence in an intradermal mouse model
(23–25). C2 and F3 modulate immune cell recruitment and proliferation in vivo (24, 25).
Although the virus lacking the gene A55R (vΔA55) has altered virulence, how A55
affects virulence and whether it recruits cullin-3 or inhibits inﬂammatory signaling
remain unknown. Thus, we investigated the effect of A55 on host innate immune
signaling pathways in vitro and in vivo and whether this modulated the immune
response in vivo and/or made for a more protective vaccine.
RESULTS
A55 speciﬁcally inhibits NF-B activation in vitro. Due to the conservation between
EVM150 and A55 and because other NF-B inhibitors exist in the VACV genome (12), a
role for A55 in NF-B signaling was investigated. HEK293T cells were cotransfected with
a plasmid expressing A55 and plasmids encoding NF-B–luciferase (Luc) and pTK-
Renilla. Cells were stimulated with tumor necrosis factor alpha (TNF-) or IL-1 or left
unstimulated, and ﬁreﬂy luciferase was measured alongside Renilla luciferase as an
internal control. Empty vector (EV) and the human BBK KLHL12 were used as negative
controls, while B14 was included as a known NF-B inhibitor. A55 expression inhibited
NF-B activity in response to both IL-1 and TNF- compared to the activity with the
EV and KLHL12 controls (Fig. 1A and B) in a dose-dependent manner (Fig. 1C). A55 also
inhibited expression of endogenous NF-B-responsive genes in response to TNF-
stimulation. For instance, transcription of IL-8 (measured by reverse transcription-
quantitative PCR [RT-qPCR]) and secretion of CXCL10 (measured by enzyme-linked
immunosorbent assay [ELISA]) were both inhibited by A55 (Fig. 1D and E). In contrast,
A55 did not inhibit the JAK-STAT (interferon-stimulated response element [ISRE]-luc) or
activator protein 1 (AP-1) promoter activity in response to alpha interferon (IFN-) or
phorbol myristic acid (PMA), respectively (Fig. 1F and G). VACV protein C6 inhibited
IFN--stimulated ISRE activity as reported previously (Fig. 1G) (26). The ability of A55 to
inhibit both IL-1- and TNF--induced stimulation of NF-B signaling suggested that it
acts at or below TAK1 phosphorylation where the IL-1R and TNFR pathways converge.
Inhibitory activity of A55 is mapped to NF-B activation downstream to IB
degradation. The NF-B pathway can be activated by overexpression of proteins
acting at speciﬁc stages. Thus, to map where A55 inhibits the pathway, a plasmid
encoding TRAF6, TRAF2, TAK1/TAB1, IKK, or p65 was cotransfected into HEK293T cells
along with pcDNA4/TO-nTAP-coA55R. Pathway activation was measured by NF-B-
luciferase expression as described above. EV and KLHL12 or B14 were used as negative
and positive controls, respectively. B14 inhibited at IKK (9) (Fig. 2A to D), while KLHL12
was not inhibitory (Fig. 2A to E). A55 expression inhibited NF-B activity in response to
TRAF2, TRAF6, TAK1, IKK, and p65 (Fig. 2A to E), and with respect to p65 the degree
of inhibition increased with greater expression of A55 (Fig. 2E). Therefore, A55 acts at
the level of p65 or downstream.
Under resting conditions, IB tethers NF-B in the cytoplasm, but upon stimulation
IB is phosphorylated by IKK, ubiquitylated, and degraded by the -TrCP/cullin-1 E3
ligase complex and proteosome (27). Free p65 phosphorylated at S536 (p-p65 S536)
translocates into the nucleus where it undergoes phosphorylation at S276. This facili-
tates recruitment of phosphorylated RNA polymerase II (p-RNAP II) and p300 (7) and
formation of the enhanceosome to initiate gene transcription. To map the inhibitory
mechanism of A55 further, HEK293T-REx cell lines with EV or vectors expressing B14 or
A55 were stimulated with TNF-, and IB levels were analyzed. As expected, B14
inhibited TNF--induced degradation of IB (Fig. 3A and B). However, although
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FIG 1 A55 inhibits NF-B-dependent signaling. (A and B) HEK293T cells were transfected with pLuc-NF-B and pRL-TK
(see Materials and Methods) and plasmids expressing Flag-tagged KLHL12, B14, or A55 or empty vector (EV). After 24
h cells were stimulated with 15 ng/ml IL-1 or 20 ng/ml TNF-, as indicated, for 6 h. Cell lysates were prepared, and the
fold increase in luciferase activity relative to Renilla activity was determined. In parallel, cell lysates were analyzed by
SDS-PAGE and immunoblotting with anti-Flag or anti--tubulin to determine protein expression levels from unstimu-
lated samples. Data are representative of three independent experiments. Statistical signiﬁcance compares results for the
EV-stimulated sample to those of the test sample. (C) The same experiment as described for panel A using increasing
plasmid concentrations of pCNDA4/TO-nTAP A55 at 25, 75, and 150 ng. Statistical signiﬁcance compares results for the
EV stimulated sample to those of the A55 stimulated sample. (D). HEK293T pCW57 stable cell lines inducibly expressing
C6, B14, or A55 were induced with 2g/ml doxycycline for 24 h, starved for 6 h in DMEM with no supplements, and left
unstimulated or stimulated with TNF for 18 h. Levels of secreted CXCL10 in the cell culture medium were assayed by
ELISA. Data shown are representative of two independent experiments carried out in triplicate. Statistical signiﬁcance
compares results for C6 stimulated cells with those for B14 or A55. (E) HEK293T-REx cell lines inducibly expressing B14
or A55 were induced with 2g/ml doxycycline for 22.5 h and left unstimulated or stimulated with 20 ng/ml TNF for
1.5 h in DMEM with no supplements. IL-8 expression levels were analyzed by RT-qPCR relative to those of GAPDH. Data
presented are representative of two independent experiments carried out in triplicate. Statistical signiﬁcance compares
the results for C6 stimulated and A55 stimulated cells. (F and G). A55 does not inhibit mitogen-activated protein kinase
(MAPK) or JAK-STAT signaling. HEK293T cells were transfected with pAP-1-Luc or pISRE-Luc, as indicated, and pRL-TK (see
(Continued on next page)
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expression levels of A55 and B14 were similar, A55 did not prevent IB degradation
(Fig. 3A and B). Consistent with reporter gene assays, this indicated that A55 acted at
or below p65 release. Phosphorylation is key to the transcriptional activity of p65. To
determine if A55 regulates phosphorylation of p65, HEK293T-REx cells expressing A55
FIG 2 A55 inhibits NF-B activation downstream of p65 release. (A to D) HEK293T cells were transfected with
pLuc-NF-B and pRL-TK together with plasmids expressing Flag-tagged KLHL12, B14, or A55 or EV and either
TRAF6, TRAF2, TAK1, or IKK, as indicated. After 24 h the fold difference in luciferase activity was determined, and
the abundance of indicated proteins was measured by SDS-PAGE and immunoblotting. (E) Cells were transfected
with reporters as described above together with a Flag-tagged p65 expression plasmid and increasing doses of
plasmid expressing A55 (25, 75, and 150 ng). Experiments are representative of three independent experiments
carried out in quadruplicate. Statistical signiﬁcance compares results with EV stimulated samples to those with the
stimulated test sample. **, P  0.01; ***, P  0.001; ****, P  0.0001.
FIG 1 Legend (Continued)
Materials and Methods) and plasmids expressing Flag-tagged KLHL12, C6, or A55 or empty vector (EV). After 24 h cells
were stimulated with 10 ng/ml PMA (F) or 1,000 U/ml IFN- (G) for 6 h. Cell lysates were prepared, and the fold increase
in luciferase activity relative to Renilla activity was determined. In parallel, cell lysates were analyzed by SDS-PAGE and
immunoblotting with anti-Flag or anti--tubulin to determine protein expression levels from unstimulated samples. Data
are representative of three independent experiments. Statistical signiﬁcance compares results with EV stimulated
samples to those with the test sample. NS, not stimulated; IB, immunoblotting. *, P  0.05; **, P  0.01; ***, P  0.001;
****, P  0.0001.
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were stimulated with TNF-, and the levels of p-p65 S536 and S276 were analyzed.
While p-p65 S536 levels were comparable in the presence or absence of A55, A55
abrogated S276 phosphorylation (Fig. 3C), which is a nuclear event (7). This suggests
that A55 may inhibit S276 phosphorylation directly or indirectly by preventing nuclear
translocation of p65.
To explore whether A55 inhibits nuclear translocation of p65, HeLa cells transfected
with Flag-tagged EV, B14, A55, or C6 were stimulated with TNF-, and the subcellular
localization of p65 was analyzed by immunoﬂuorescence (Fig. 4A). Cells were costained
with anti-Flag and anti-p65, and 4=,6=-diamidino-2-phenylindole (DAPI) was used to
stain DNA; then the numbers of cells exhibiting nuclear exclusion of p65 were deter-
mined (Fig. 4B). As expected, almost 100% of the EV untreated cells exhibited nuclear
exclusion of p65 in contrast to p65 exclusion in only 10% of EV-stimulated cells (Fig. 4B),
and B14 prevented nuclear translocation of p65, while protein C6 did not (Fig. 4B). In
comparison, A55 inhibited translocation of p65 in 62% of transfected cells following
stimulation (Fig. 4B). Collectively, this maps the inhibitory activity of A55 prior to
nuclear translocation of free NF-B but after IB degradation.
A55 targets importins to inhibit NF-B activation. The nuclear translocation of
NF-B p65 is regulated by importin-1 to -4/importin- shuttling, dependent upon
cell type and stimulus (3–5). To determine if A55 targets the nuclear importins, the
interaction of A55 and importins was investigated following immunoprecipitation (IP)
of Flag-tagged KPNA1, -2, or -3 from transfected HEK293T cells that were infected with
wild-type (WT) VACV WR. Coimmunoprecipitation (co-IP) of A55 was tested using an
A55-speciﬁc antibody (23). A55 coprecipitated with KPNA2, but not KPNA1 or -3,
whereas C6 was not coprecipitated (Fig. 5A). Consistent with this, endogenous KPNA2
but not KPNA1 coprecipitated with transfected Flag-tagged A55 (Fig. 5B). KPNA2 is
required for p65 translocation, and therefore the interaction of p65 and KPNA2 was
investigated in the presence of A55 or B14. Transfected hemagglutinin (HA)-p65 was
immunoprecipitated, and the levels of coprecipitated KPNA2 were reduced in the
presence of A55 (Fig. 5C), suggesting that A55 may block interaction of KPNA2 and p65.
As A55 is a predicted BBK E3 ligase adaptor, the levels of KPNA2 following infection
with the WT VACV WR strain expressing A55 (vA55), a mutant lacking the A55R gene
(vΔA55), or a revertant virus with A55R inserted back into vΔA55 and under its
FIG 3 A55 acts downstream of IB degradation and prevents phosphorylation of p65 on Ser276. HEK293T-REx cell
lines inducibly expressing B14 or A55 or empty vector (EV) were induced with 2 g/ml doxycycline for 24 h and
then stimulated with 40 ng/ml TNF- for 20 min. The levels of IB, Flag-tagged B14 or A55, and -tubulin were
determined by SDS-PAGE and immunoblotting. (B) The level of IB relative to that of tubulin was quantiﬁed by
densitometry from three independent experiments. Statistical signiﬁcance compares results of the EV stimulated
condition with those of the B14 or A55 stimulated condition. *, P  0.05. (C). HEK293T-REx cell lines inducibly
expressing A55 or EV were induced with doxycycline as described for panel A and then left unstimulated (0) or
stimulated with 40 ng/ml TNF- for 30 or 60 min. The levels of indicated proteins and phosphorylation of p65 were
determined by SDS-PAGE and immunoblotting. Loading and p65 levels were controlled for using anti-tubulin and
anti-p65, respectively. The immunoblot shown is representative of three independent experiments.
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endogenous promoter (vΔA55Rev) were investigated. Notably, the levels of KPNA2 did
not alter during infection or transfection (Fig. 5D).
A55 inhibits NF-B in a Kelch-dependent manner independent of cullin-3
binding. Typically, BBKs recruit cullin-3 via their BTB domains and recruit their sub-
strates to the cullin-3 E3 ligase complex via their C-terminal Kelch domains. Therefore,
a possible interaction between A55 and cullin-3 was investigated, and this showed that
endogenous cullin-3 coprecipitated with A55 but not with B14 (Fig. 6A). This interaction
was conﬁrmed by reciprocal IP of overexpressed Myc-tagged cullin-3 or cullin-5 (Fig.
6B). Subdividing A55 into its BTB and Kelch domains (Fig. 6C) showed that precipitation
of endogenous cullin-3 was achieved by the BTB domain but not the Kelch domain of
A55 (Fig. 6D). In contrast, the Kelch domain was sufﬁcient to co-IP endogenous KPNA2
(Fig. 6E). To determine if the Kelch domain mediated inhibition of NF-B activation,
HEK293T-REx cells expressing the full-length A55 or the BTB-BACK or Kelch domain
separately were stimulated with IL-1 or TRAF6 cotransfection, and NF-B luciferase
activity was measured. Despite higher levels of BTB-BACK expression (Fig. 6G), only the
Kelch domain inhibited IL-1- and TRAF6-induced NF-B activation (Fig. 6F). We next
tested if either domain was sufﬁcient to prevent NF-B p65 nuclear translocation. HeLa
cells transfected with Flag-tagged C6, A55, A55 BTB, or A55 Kelch were stimulated with
TNF-, and the subcellular localization of p65 was analyzed by immunoﬂuorescence as
before. Interestingly, both domains alone appeared to inhibit p65 translocation follow-
ing TNF- stimulation as efﬁciently as full-length A55 (Fig. 7A and B). However, the
inhibitory activity of A55 BTB-BACK correlated with induction of cellular vacuolization
(Fig. 7C), compromising the conclusion that this was indirect inhibition by BTB-BACK.
Thus, A55 can inhibit NF-B activation in a Kelch-dependent and cullin-3-independent
manner.
FIG 4 A55 inhibits p65 nuclear translocation. (A) Representative immunoﬂuorescence staining of p65 localization
in HeLa cells transfected with 1,000 ng/well of a six-well plate of plasmids encoding Flag-tagged B14, A55, C6, or
EV and left untreated or stimulated with 20 ng/ml TNF- for 30 min. Cells were stained with DAPI (blue), anti-Flag
(red), and anti-p65 (green) antibodies. (B) Percentage of transfected cells with nuclear p65. Results are represen-
tative of three independent experiments carried out in triplicate, counting 100 cells per sample. Statistical
signiﬁcance compares the results of the EV stimulated sample with those of the A55, B14, or C6 stimulated sample.
Scale bar, 10 M. ****, P  0.0001.
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A55 inhibits CD8 T-cell proliferation and activation in the acute phase of
infection. The potential role of A55 as an immunomodulator was investigated next by
measuring the immune cell number and activation status, as well as immunological
memory, in C57BL/6 mice infected intradermally with vA55, vΔA55, and vΔA55Rev
(28, 29).
As expected, the lesion size was increased upon infection with vΔA55 compared to
lesions in control virus infections (data not shown) (23). On day 7 postinfection (p.i.), the
absolute cell numbers of immune cells in the spleen (Fig. 8A) and draining lymph nodes
(DLN) (Fig. 8B) were counted. The total splenic and DLN cell number and the numbers
of CD8 T cells and macrophages in these organs were signiﬁcantly increased during
infection with vΔA55 compared to levels with control virus infection, while no signif-
icant changes were observed for CD4 T cells, neutrophils, or NK cells (Fig. 8A and B).
CD8 T cells also showed enhanced activation (increased CD69 expression) at day 7 p.i.
(Fig. 8C and D), and this correlated with increased VACV-speciﬁc CD8 T cells at days
7 and 28 p.i. (Fig. 8E). In contrast, no increase in NK cell or CD4 T-cell activity was
observed (Fig. 8C and D). Interestingly, the increase in CD8 T-cell activation upon
infection with vΔA55 was still apparent at day 28 p.i. (Fig. 8C to E), whereas T-cell
activation in the WT infection had returned to basal level. Therefore, we tested if loss
of A55 enhanced CD8 T-cell memory and, if so, if immunization with vΔA55 provides
better protection to challenge.
A55 deletion enhances CD8 T-cell memory and provides protection to VACV
challenge. Strong CD8 T-cell immunological memory is desirable following vaccina-
FIG 5 A55 targets host importin KPNA2. (A to C) Representative immunoblots showing anti-Flag or anti-HA
immunoprecipitation (IP), as indicated, of cleared lysates from HEK293T cells lysed in NP-40 (A and B) or RIPA (C)
buffer and subjected to SDS-PAGE and immunoblotting with the indicated antibodies. For the experiment shown
in panel A, HEK293T cells were transfected with plasmids encoding Flag-KPNA1, KPNA2, KPNA3, or EV, and 24 h
later cells were infected with WT VACV at 5 PFU/cell for 18 h. For the experiment shown in panel B, HEK293T-REx
cells inducibly expressing B14, A55, or EV were induced with 2 g/ml doxycycline for 36 h. For the experiment
shown in panel C, pCW57 cell lines expressing B14 or A55 inducibly were induced with 2 g/ml doxycycline for 24
h and then transfected with a plasmid encoding HA-tagged p65. Input, cleared cell lysate; IP, immunoprecipitate;
IB, immunoblot. In the right panel, the amount of KPNA2 coprecipitating with p65 in the presence of A55 or B14
was quantiﬁed by densitometry. Data are the average of three independent experiments. The asterisk in panel B
indicates the immunoglobulin light chain. (D) Endogenous KPNA2 levels in cell lysates from HeLa cells infected for
3, 6, or 9 h with vA55, vΔA55, or vΔA55Rev at 5 PFU/cell or left noninfected (NI). Tubulin was used as a loading
control, and VACV protein D8 was used as a control for infection. The immunoblot shown is representative of two
independent experiments.
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FIG 6 A55 inhibits NF-B activation in a cullin-3-independent manner via its Kelch domain. Shown are immuno-
blots following immunoprecipitation (IP) of cleared cell lysates from HEK293T-REx cells inducibly expressing B14,
A55, or EV (A), B14 or A55 (B), or B14, A55, A55-BTB, A55-Kelch, or EV (D) at 24 h postinduction with 2 g/ml
doxycycline and lysis in NP-40 (A and D) or RIPA (B) lysis buffer. Samples were subjected to SDS-PAGE and
immunoblotting with the stated antibodies. (A and D) Flag-tagged immunoprecipitation and immunoblotting for
endogenous cullin-3 (CUL3). (B) Reciprocal IP with protein G-Sepharose supplemented with mouse anti-Myc using
cell lysates prepared 24 h posttransfection with pCDNA-Myc-CUL3 or -CUL5. (C) Schematic of A55 domains.
Full-length A55 from amino acid 1 to 565 was divided into the N-terminal BTB-BACK-containing domain and the
C-terminal Kelch domain as depicted. (E) Flag IP as described for panel D in RIPA buffer using the pCW57 HEK cell
lines expressing B14, A55, A55-BTB, or A55-Kelch and blotting for endogenous KPNA2. Input, cleared lysate; IP,
immunoprecipitate; IB, immunoblot; *, antibody heavy/light chain. (F) HEK293T cells were transfected with
pLuc-NF-B and pRL-TK together with 100 ng of pcDNA3-Flag-KLHL12, 20 ng of pcDNA4-coB14R-Flag, of 100 ng of
pcDNA4/TO-nTAP-coA55R, pcDNA4/TO-nTAP-coA55R-BTB, pcDNA4/TO-nTAP-coA55R-Kelch, or pcDNA4/TO-EV. In
the experiment shown in the right panel, cells were also transfected with plasmid expressing TRAF6. After 24 h cells
were either left unstimulated or stimulated with 15 ng/ml IL-1 for 6 h, and the luciferase and Renilla activities were
measured. Statistical signiﬁcance compared results with EV (stimulated) to those with the test samples. (G). Lysates
from cells treated (as described for the left panel of F) were analyzed by SDS-PAGE and immunoblotting with the
indicated antibodies. Data shown in all panels are representative of three independent experiments. **, P  0.01;
***, P  0.001; ****, P  0.0001.
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tion (30). To test if A55 modulates immunological memory, the killing activity of splenic
CD8 T cells and NK cells was assessed at day 28 p.i. with vA55, vΔA55, or vΔA55Rev.
Killing of VACV-infected EL4 cells by splenic T cells isolated 28 days p.i. was signiﬁcantly
increased for all three infected groups versus levels for the mock-infected control (Fig.
9A). EL4 killing was also greater with CD8 T cells isolated from mice immunized with
vΔA55 than with those from mice immunized with control viruses (Fig. 9A). Notably
T-cell-mediated killing was reduced to basal levels by the addition of an anti-CD8
antibody, showing that cytolysis was CD8 T cell speciﬁc (Fig. 9B). In contrast, no
differences between the vA55 or vΔA55 groups were observed in the ability of NK cells
to kill VACV-infected P815 cells following immunization (Fig. 9A).
To test if vΔA55 would be a better vaccine, mice infected intradermally with vA55,
vΔA55, or vA55Rev were challenged intranasally at day 28 p.i. with vA55. Weight loss
and viral titers in the lungs were quantiﬁed on days 1 and 4 p.i. Weight loss was
FIG 7 The A55 Kelch domain inhibits p65 nuclear translocation. (A) Representative immunoﬂuorescent staining of
p65 localization in HeLa cells transfected with plasmids encoding Flag-tagged B14, A55, C6, or EV and left untreated
or stimulated with 40 ng/ml TNF- for 30 min. Cells were stained as described in Materials and Methods with DAPI
(blue), anti-Flag (red), and anti-p65 (green). Scale bar, 20 M. (B) Percentage of transfected cells with nuclear p65.
Data are representative of three independent experiments. Statistical signiﬁcance compares results of EV (stimu-
lated) with those of A55, B14, or C6 (stimulated). (C) Representative image of HeLa cells transfected with a plasmid
encoding A55-BTB. Scale bar, 10 M. Data are representative of three independent experiments. *, P 0.05; **, P
0.01.
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signiﬁcantly reduced from day 3 to day 7 p.i. in vΔA55-immunized mice compared to
levels in the control groups (Fig. 9C). This was accompanied by a decrease in viral titer
in the lungs of vΔA55-immunized mice at day 4 p.i. (Fig. 9D). Taken together, these data
show that vΔA55-immunized mice are better protected following intranasal challenge
and clear viral infection more quickly, making vΔA55 a more efﬁcacious vaccine.
DISCUSSION
During evolution with their hosts, viruses have evolved strategies to evade or
suppress the host immune system. The study of virus-encoded proteins that modulate
the immune response (immunomodulators or immunoevasins) has increased our un-
derstanding of not only virus immune evasion and pathogenesis but also cellular
FIG 8 Infection with vΔA55 induces enhanced CD8 T-cell response. (A and B) Female C57BL/6 mice (6 to 8 weeks old; n 5) were injected intradermally in
the ear pinnae with 5 103 PFU of puriﬁed vA55, vΔA55, or vΔA55Rev or with PBS. At 7 days p.i. the total numbers of cells in spleen and draining lymph node
(DLN) were determined. The absolute numbers of CD8 or CD4 T cells from spleen or DLN and the number of splenic NK cells, macrophages, and neutrophils
were determined by ﬂuorescence-activated cell sorting. (C and D) The expression levels of CD69 on splenic NK, CD4, and CD8 cells and on DLN CD4 and
CD8 cells were quantiﬁed. (E) Number of splenic, VACV-speciﬁc, DimerX-positive CD8 T cells at days 7 and 28 p.i. Statistical analysis compares results with
vΔA55 to those with vA55 or vA55Rev. Data shown are representative of two independent experiments. *, P  0.05; **, P  0.01; ***, P  0.001.
Vaccinia Protein A55 Blocks NF-B Activation Journal of Virology
May 2019 Volume 93 Issue 10 e00051-19 jvi.asm.org 11
 o
n
 M
ay 30, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
signaling pathways and regulators of the immune response to infection. VACV encodes
scores of immunomodulators, and a mutant virus lacking one of these, called A55,
increased immunopathology following intradermal infection (23). This observation and
the report that the orthologue of A55 in ectromelia virus, EVM150, inhibited NF-B (13)
led us to investigate the function of A55 further and the consequence of A55 expres-
sion on the NF-B signaling pathway in vitro and on the immune response to infection
in vivo. This report shows that A55 targets the cellular importin KPNA2 to dysregulate
p65 translocation and restrict NF-B activation. Furthermore, immunization with a virus
lacking A55 induced a stronger CD8 T-cell response to VACV and better protection
against VACV challenge.
Consistent with a report on EVM150 (13), data presented show that A55 inhibits
cytokine expression and NF-B-luciferase activity in response to TNF- and IL-1 by
preventing p65 translocation and without affecting IB levels. This suggested a
possible modulation of cellular factors needed for p65 translocation. Consistent with
this, A55 coprecipitated with KPNA2, part of the importin complex. Further, the
interaction seen between KPNA2 and p65 was reduced in the presence of A55,
indicating that A55 may disrupt KPNA2-p65 complex formation to inhibit p65 translo-
cation. This observation is relevant to understanding which KPNAs control NF-B p65
translocation.
FIG 9 Infection with vΔA55 induces enhanced CD8 T cell cytotoxicity and better protection to VACV challenge.
Mice were infected as described in the legend of Fig. 7, and the immune response was analyzed at 28 days p.i. (A)
51Cr release assay assessing the ability of splenic CD8 T cells to lyse VACV-infected EL4 cells or of splenic NK cells
to lyse VACV-infected P815 cells. Data are presented as the percentage of cell lysis at various effector-to-target (E/T)
cell ratios. (B) 51Cr release assay conducted as described for panel A but with cells preincubated with a monoclonal
anti-CD8 antibody. (C and D) At 28 days p.i. mice immunized with vA55, vΔA55, or vΔA55Rev were infected with
107 PFU of WT VACV, and weight change and pulmonary virus titers were determined. Statistical analysis compares
results with vΔA55 to those with vA55 or vA55Rev. Data shown are representative of two independent experi-
ments. **, P  0.01; ***, P  0.001.
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Humans encode a family of importins among which KPNA1 to -4 and KPNA6 are
implicated in regulating NF-B signaling. The interaction of KPNA1 to -3 with NF-B was
identiﬁed from an in vitro screen using importins puriﬁed from bacteria (5), and an
interaction of KPNA2 to -4 with p65 was observed both in vitro and in vivo; the
KPNA2-p65 interaction was also nuclear localization signal (NLS) dependent (4). Con-
versely, KPNA2-p65 binding was not observed using recombinant protein from insect
cells, and the authors suggested that interaction with KPNA3 and -4 (KPNA3/4) is more
biologically relevant (4). However, this evidence may only suggest that KPNA2 does not
interact directly with p65 in the absence of pathway stimulation or posttranslation
modiﬁcation (4) and that KPNA2-p65 binding was enhanced following TNF- stimula-
tion (4). A small interfering RNA (siRNA) screen of the impact of importins on p65
translocation following TNF- stimulation indicated that KPNA2 and KPNA6 contribute
the most (3). More recently siRNA-mediated knockdown of KPNA2 was shown to impair
p65 translocation and NF-B-dependent gene expression in rat pancreatic acinar cells
(6). Collectively, the literature suggests that multiple importins regulate p65 transloca-
tion, with KPNA2 playing a leading role. KPNA redundancy may explain why A55-
mediated inhibition of p65 translocation is incomplete and why its inhibition is less
efﬁcient than that of B14, which targets IKK (9), or that of A49, which targets -TrCP
(11).
Targeting of importins to dysregulate cellular signaling has been reported for RNA
viruses (31–34). For instance, Japanese encephalitis virus NS5 targets KPNA2 to -4, with
binding of KPNA3/4, preventing IRF3 translocation (32). Hepatitis C virus NS3/4A
restricts IRF3 and NF-B translocation by targeting KPNAB1 (33), and the Hantaan virus
nucleocapsid protein inhibits p65 translocation and coprecipitated with overexpressed
KPNA1, -2, and -4 (34). However, this report is the ﬁrst describing speciﬁc targeting of
KPNA2 to disrupt p65-KPNA2 complex formation and subsequently NF-B signaling
and reinforces the importance of KPNA2 in NF-B translocation. A55 lacks a canonical
NLS and is cytoplasmic; it is therefore unlikely to be a KPNA2-dependent cargo but,
rather, functions in the cytoplasm. While targeting KPNA2 reduces NF-B signaling, it
may also have other consequences on nuclear shuttling that may contribute to the
in vivo phenotype of vΔA55. The A55 N-terminal BTB domain, which binds cullin-3, may
also contribute to this phenotype.
Although the inhibition of NF-B activation by A55 depends on the A55 Kelch
domain and is independent of cullin-3 binding, the BTB-BACK domain likely also has an
important function. To start to address this, the cocrystal structure of the A55 BTB-BACK
domain bound to cullin-3 was determined and revealed an overall interaction that is
conserved between cullin-3 and other cellular binding partners such as KLHL3, a human
BTB (42). Nonetheless, the afﬁnity of A55 BTB-BACK for cullin-3 was much higher than
for the interaction of cullin-3 with other cullin-3 binding partners, suggesting that A55
would be an effective competitor for the interaction of cullin-3 and its binding partners
(42).
Data presented here are consistent with those for the ectromelia virus orthologue
of A55, EVM150, with one exception. Both proteins coprecipitated with cullin-3 via an
N-terminal BTB domain, and both inhibited NF-B activation in a cullin-3-independent
manner. With EVM150, however, inhibition of p65 translocation and of NF-B signaling
was reported to require only the BTB domain, and the Kelch domain lacked this
inhibitory activity (13). In contrast, the A55 Kelch domain mediated coprecipitation with
KPNA2 and inhibition of NF-B activation, and this ﬁts with inhibition being cullin-3
independent. Discrepancies might reﬂect precisely where A55 and EVM150 were
subdivided, subtle differences in amino acid composition, or changes in solubility and
expression levels of the BTB and Kelch domains. Concerning these possibilities, ﬁrst, we
expressed the A55 BTB domain as amino acids 1 to 251, a region which includes the
BACK and 3-box domains. The Kelch domain was expressed as amino acids 252 to 565.
In contrast, the study of EVM150 expressed the BTB domain only, lacking both the BACK
and 3-box domains. Second, we observed that the A55 BTB-BACK domain expressed at
higher levels than either the Kelch domain or full-length protein, and this was adjusted
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for the reporter assays by modulating the amount of plasmid transfected. Finally,
expression of A55 BTB-BACK induced cellular vacuolization, a phenotype associated
with cullin-3 depletion (35). Therefore, the apparent inhibitory activity of A55 BTB-BACK
and potentially of EVM150-BTB may be due to overexpression and cullin-3 saturation
leading to inhibition of p65 translocation due to loss of cell viability. While the Kelch
domain alone was sufﬁcient to inhibit NF-B signaling, the ability of A55 to bind cullin-3
might still affect NF-B signaling during infection, when protein levels may be lower
and other viral proteins are present, and particularly in vivo, where NF-B activation
needs to be counteracted in different cell types. The existence and conservation of
several poxviral BBKs suggest that they play an important role during infection.
Inﬂammation and expression of NF-B-dependent cytokines are important for the
development and proliferation of effector and memory T-cell populations (36). Consis-
tent with this, deletion of the NF-B inhibitor A55 modulated the immune response
during acute infection and led to enhanced VACV-speciﬁc CD8 T-cell memory. This is
reminiscent of a VACV mutant lacking NF-B inhibitor N1 causing enhanced CD8
T-cell memory and effector function (37). However, to conﬁrm that it is the ability of
A55 to inhibit NF-B activation that results in the enhanced CD8 T-cell memory, rather
than other functions of the A55 protein, it will be necessary in the future to study the
immunogenicity of a virus expressing a mutant A55 protein that is no longer able to
bind to cullin-3. Understanding the signals derived from acute infection that mediate
development of immunological memory is key to effective future vaccine design. VACV
mutants lacking speciﬁc immunomodulators are useful tools to understand the mech-
anisms underlying and controlling immunological memory but also suggest ways to
produce VACV-based vaccines that induce enhanced CD8 T-cell memory.
In conclusion, this report shows that VACV protein A55 inhibits NF-B activation and
is the 11th VACV-encoded NF-B inhibitor (8). Despite the presence of other NF-B
inhibitors, loss of A55 gives an in vivo phenotype leading to enhanced CD8 T-cell
memory and better protection against reinfection. Mechanistically, A55 coprecipitates
with KPNA2 via its Kelch domain to disrupt p65-KPNA2 interaction and impair p65
nuclear translocation.
MATERIALS AND METHODS
Ethics statement. This work was conducted under license PPL 70/8524 from the UK Home Ofﬁce
according to the Animals (Scientiﬁc Procedures) Act 1986.
Cells, plasmids, reagents, and viruses. All reagents were purchased from Sigma unless otherwise
stated. BSC-1 (ATCC) and HEK293T cells were grown in high-glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Gibco), HeLa cells (ATCC) were grown in minimal essential medium (MEM; Gibco), and EL4
(H-2b; ATCC) and P815 (ATCC) cells were grown in RPMI medium (Gibco). All media were supplemented
with 10% fetal bovine serum (FBS; Pan Biotech), nonessential amino acids (NEAA), and 50 g/ml
penicillin-streptomycin (P-S) at 37°C in a 5% CO2 atmosphere. All plasmids used and those constructed
during this study are listed in Table 1. Plasmids were generated using conventional restriction enzyme
digest and ligation using the primers with restriction enzyme sites indicated in Table 1. VACV strain WR
recombinants vA55 (plaque puriﬁed wild-type), vΔA55 (A55 deletion mutant), and vΔA55Rev (revertant
virus with A55R reinserted into vΔA55) were described previously (23). Infectious virus titers (number of
PFU/milliliter) were determined by plaque assay on BSC-1 cells.
HEK293T-REx, pLDT, and pCW57 cell line generation. HEK293T-REx cells were constructed using
the pcDNA4/TO plasmids listed in Table 1 along with plasmid pcDNA6-TR encoding the tetracycline
inducible promoter repressor. After transfection into HEK293T cells using LT1 transfection reagent, cells
were selected using blasticidin and zeocin, according to the manufacturer’s instructions (Invitrogen). The
pCW57 or pLDT plasmids listed in Table 1, along with the EV as a control, were cotransfected with the
packaging (pCMV-PACK) and envelope (pCMV-ENV) plasmids for lentivirus production in HEK293T or
HEK293T TetR (pLDT-TetR transduced HEK293T) cells, respectively, using LT1 transfection reagent
(MirusBio). After 48 h the medium was ﬁltered and transferred to fresh monolayers of HEK293T cells, and
3 days later 2 g/ml puromycin (Invivogen) was added. Transduction and expression were conﬁrmed by
the addition of 2 g/ml doxycycline and immunoblotting of cell lysates.
Luciferase reporter assay. HEK293T cells were transfected with 100 ng of pcDNA4/TO-EV, 100 ng of
pcDNA4/TO-nTAP-coA55R, 25 ng of pcDNA4/TO-nTAP-coA55R-BTB, 100 ng of pcDNA4/TO-nTAP-coA55R-
Kelch, 100 ng of pcDNA3-Flag-KLHL12, 20 ng of pcDNA3-Flag-coB14R (9) or 20 ng of pcDNA4/TO-cTAP-
C6L (38) along with 10 ng of plasmid pTK-Renilla (pRL-TK; Promega) and 45 ng of pLUC-NF-B (R.
Hofmeister, University of Regensburg, Germany), pLUC-AP-1 (Andrew Bowie, Trinity College Dublin), or
pLUC-ISRE (Promega) using LT1 transfection reagent (MirusBio, Ltd.). All conditions were transfected with
equal amounts of total plasmid DNA by supplementation with pcDNA/TO-EV. Simultaneously, where
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TABLE 1 Plasmids constructed or used in this study
Constructed plasmida Description or primer sequenceb
Restriction
enzyme
Reference or
source
pcDNA4/TO-nTAP/nHA/cTAP Mammalian expression vector with N-terminal or C-terminal Strep-I and
Strep-II tag followed by Flag tag or with a C-terminal HA tag only or
a C-terminal Flag tag only, all under the control of a CMV promoter;
Ampr, Zeor
Invitrogen
pcDNA4/TO-nTAP-A55R GACGCGGCCGCGAACAACAGCAGCGAGC NotI This study
GACTCTAGATCAGCTTCCGATGAAGC XbaI
pcDNA4/TO-nTAP-A55R BTB GACGCGGCCGCGAACAACAGCAGCGAGC NotI This study
GACTCTAGATTAGTGGTATCTGGGGAAGC XbaI
pcDNA4/TO-nTAP-A55R Kelch GACGCGGCCGCGTCCATCGAGCTGATCAGC NotI This study
GACTCTAGATCAGCTTCCGATGAAGC XbaI
pcDNA4/TO-P65-cTAP ATATCGGATCCGCCACCATGGACGAACTGTTCCCCCTCATCT BamHI This study
ATACTGCGGCCGCGGAGCTGATCTGACTCAGC NotI
pcDNA4/TO-P65-HA ATATCGCGGCCGCGGACGAACTGTTCCCCCTCATCT NotI This study
ATACTTCTAGATTAGGAGCTGATCTGACTCAGC XbaI
pCDNA4/TO-B14R-cTAP GCGCGGATCCACCATGACGGCCAACTTTAGTACCCACGTC
GCTGCCTCCTCCCTTTTCAAACTGAGGATGAGACCACGCGGC
CGCATTCATACGCCGGAATATG
GCCGCTGGCTCCCTTCTCGAACTGGGGGTGGCTCCAGCTTCCG
CCTCCGCTGCCTCCTCCCTT
BamHI This study
CGGCTCTAGACCGCGGTTACTTGTCGTCATCGTCATCCTTGT
AGTCCTCGCCGCTGGCTCCCTTCTC
XbaI
pCDNA6/TR Mammalian expression vector with the Tet repressor under the control
of a CMV promoter; Ampr, Blastr
Invitrogen
pCDNA3-Flag/HA/Myc Mammalian expression vector with Flag or HA tag under the control of
a CMV promoter; Ampr
Invitrogen
pcDNA3-HA-TAK1 GCTGCGGCCGCTTCTACAGCCTCTGCC NotI This study
GTCTCTAGATCATGAAGTGCCTTGTCG XbaI
pcDNA3-HA-TAB1 GCTGCGGCCGCATGGCGGCGCAGAGGAGGAGC NotI This study
GTCTCTAGACTACGGTGCTGTCACCACGCT XbaI
pcDNA3-Flag-KLHL12 Gift from
Randall T.
Moon
pcDNA3-Flag-CUL3 Addgene, 19893
pcDNA3-Flag-CUL5 Addgene, 19895
M5P-Flag Mammalian expression vector with Flag tag under the control of the
murine leukemia virus long terminal repeat promoter; Ampr
M5P-Flag-TRAF6 Gift from
Andrew
Bowie
pCW57-GFP-P2A-MCS Lentiviral expression plasmid with GFP in MSC1 and P2A skip sequence
followed by MCS2 under the control of a CMV promoter; Ampr, Puror
Addgene, 89181
pCW57-GFP-P2A-nTAP-A55R CGACGCGTATGTGGTCTCATCCTCAGTTTG MluI This study
GCAGGATCCTCAGCTTCCGATGAAGCTTTC BamHI
pCW57-GFP-P2A-nTAP-A55R
BTB
CGACGCGTATGTGGTCTCATCCTCAGTTTG MluI This study
GCAGGATCCTCAGTGGTATCTGGGGAAGC BamHI
pCW57-GFP-P2A-nTAP-A55R
Kelch
CGACGCGTATGTGGTCTCATCCTCAGTTTG MluI This study
GCAGGATCCTCAGCTTCCGATGAAGCTTTC BamHI
pCW57-GFP-P2A-nTAP-B14R CGACGCGTATGTGGTCTCATCCTCAGTTTG MluI This study
GCAGGATCCTCAATTCATACGCCGGAATAT BamHI
pCW57-GFP-P2A-nTAP-C6L CGACGCGTATGTGGTCTCATCCTCAGTTTG MluI This study
CGACGCGTTTATCATCTGTCCACGTCGT MluI
pCMV-PACK Packaging plasmid for lentivirus production with HIV Gag, Pol, Rev, and
Tat under the CMV promotor; Ampr
Gift from H.
Laman
pCMV-ENV VSV-G pseudotyped envelope protein under the CMV promoter for
lentivirus production; Ampr
Gift from H.
Laman
pLDT-TetR Lentiviral expression plasmid constitutively expressing the tetracycline
promoter repressor; Ampr, Neor
41
(Continued on next page)
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stated, plasmids encoding TRAF2, TRAF6 (Andrew Bowie, Trinity College Dublin), TAK1, TAB1, IKK (Alain
Chariot, University of Leige), and p65 were cotransfected. After 24 h cells were stimulated with 20 ng/ml
TNF-, 15 ng/ml IL-1, 1,000 U of alpha interferon (IFN-) (all Peprotech), or 10 ng/ml phorbol 12-
myristate 13-acetate (PMA) for 6 h. Cells were lysed in passive lysis buffer (Promega), and ﬁreﬂy/Renilla
luciferase activity was measured using a FLUOstar Omega plate reader (BMG Labtech). Relative lumi-
nescence levels were calculated by normalizing ﬁreﬂy luminescence to Renilla luminescence and are
represented as relative to levels of the nonstimulated EV condition.
RT-qPCR. RNA extraction, cDNA synthesis, and RT-qPCR were carried out as described previously (39).
qPCR used primers for IL-8 (AGAAACCACCGGAAGGAACCATCT and AGAGCTGCAGAAATCAGGAAGGCT)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (TCGACAGTCAGCCGCATCTTCTTT and ACCA
AATCCGTTGACTCCGACCTT).
ELISAs. HEK293T-REx cell lines were starved for 6 h in DMEM without supplements before being
stimulated for 18 h with 20 ng/ml TNF-. CXCL10 in the medium was measured using a CXCL10/IP-10
DuoSet ELISA kit (R&D Systems) and a FLUOstar Omega plate reader (BMG Labtech). Experiments were
carried out in triplicate and measured with technical repeats.
Translocation assay and immunoﬂuorescent staining. HeLa cells were transfected with plasmids
encoding N-terminal tandem afﬁnity puriﬁcation (TAP)-tagged C6, B14, or A55 using LT1 transfection
reagent (MirusBio). After 24 h cells were starved in DMEM without serum for 3 h, followed by stimulation
with 40 ng/ml TNF- for 30 min. Cells were washed three times in ice-cold phosphate-buffered saline
(PBS) and processed for immunoﬂuorescence staining and imaging as described previously (38). Rabbit
anti-Flag and mouse anti-p65 were used as the primary antibodies, and goat anti-rabbit 546 and donkey
anti-mouse 488 were used as the secondary antibodies. Images were analyzed using Zeiss Zen micro-
scope software and ImageJ. Experiments were performed in triplicate and carried out three times. For
each repeat, 100 Flag-positive cells were counted for each condition, and the numbers of cells showing
clear nuclear exclusion of p65 were counted to calculate the percentage.
Coimmunoprecipitation. HEK293T-REx cells were induced with 2 g/ml doxycycline for 24 h and
lysed in either phosphate-buffered saline supplemented with 0.5% NP-40 (Igepal CA-630) and protease
inhibitor or in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 0.5 M
EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS supplemented with protease inhibitor) where
stated. Proteins were immunoprecipitated as described previously (38) with M2 Flag-tagged beads,
HA-tagged beads, or Fastﬂow G-Sepharose (GE Healthcare) incubated previously with mouse monoclonal
anti-Myc tag clone 9B11 (catalog number 2276; Cell Signaling Technology [CST]) at 1:50. After the ﬁnal
wash, beads were incubated in 4 sample loading dye (lithium dodecyl sulfate [LDS]; 0.5 M Tris, pH 6.8,
40% glycerol, 6% SDS, 1% bromophenol blue, and 0.8% -mercaptoethanol) and analyzed by immuno-
blotting.
Immunoblotting and antibodies. Samples were prepared by the addition of LDS, boiled, and then
separated by electrophoresis in an SDS-polyacrylamide gel in Tris-glycine-SDS (TGS) buffer (20 mM Tris,
192 mM glycine, 1% [wt/vol] SDS) before being transferred to a nitrocellulose membrane (GE Healthcare)
in Tris-glycine (TG) buffer (20 mM Tris-HCl, pH 8.3, 150 mM glycine) using the Turboblot system (BioRAD).
Membranes were blocked in 5% milk in Tris-buffered saline (10 mM Tris, 150 mM NaCl), pH 7.4, with 0.1%
(vol/vol) Tween 20 (TBS-T) for 60 min before being incubated with the primary antibody overnight at 4°C.
Primary antibodies were rabbit polyclonal anti-KPNA2 (ab70160; Abcam), rabbit polyclonal anti-IB
(9242; CST), anti-p65 S536 (S3010S; CST), anti-p65 S276 (sc-101749; Santa Cruz), rabbit monoclonal
anti-cullin-3 clone EPR3195 (ab108407; Abcam), anti-Flag (F7425), mouse anti-myc 9B11 (2276; CST),
anti-tubulin (05-829; Millipore), mouse monoclonal anti-KPNA1 187.1 (sc-101292; Santa Cruz), anti-p65
clone F-6 (sc-8008; Santa Cruz), and anti-phospho-IB (9246; CST); antibodies to VACV proteins were
rabbit polyclonal anti-C6 (38) or A55 (23) or mouse monoclonal D8 clone AB1.1 (40). Membranes were
TABLE 1 (Continued)
Parental or constructed plasmida Description or primer sequenceb
Restriction
enzyme
Reference or
source
pLDT-MCS Lentiviral expression plasmid with expression under the control of a
tetracycline-inducible CMV promoter; Ampr, Puror
41
pLDT-nTAP-A55R CTAGCTAGCATGTGGTCTCATCCTCAGTTTG NheI This study
GCGGTCGACTCAGCTTCCGATGAAGCTTTC SalI
pLDT-nTAP-B14R CTAGCTAGCATGTGGTCTCATCCTCAGTTTG NheI This study
CGGAATTCTCAATTCATACGCCGGAATAT EcoRI
pLDT-nTAP-C6L CTAGCTAGCATGTGGTCTCATCCTCAGTTTG NheI This study
GAGCTCGAATTCTTATCATCTGTCCACGTCGT EcoRI
pCAGGS-Flag Mammalian expression vector with a Flag tag under the control of the
CMV immediate early promoter; Ampr
pCAGGS-Flag-KPNA1 31
pCAGGS-Flag-KPNA2 31
pCAGGS-Flag-KPNA3 31
aParental plasmids are in boldface. GFP, green ﬂuorescent protein; MCS, multiple cloning site; CMV, cytomegalovirus.
bRestriction sites are underlined. Ampr, ampicillin resistance; Puror, puromycin resistance; Neor, neomycin resistance; Zeor, zeocin resistance; Blastr, blasticidin
resistance; VSV-G, vesicular stomatitis virus protein G.
Pallett et al. Journal of Virology
May 2019 Volume 93 Issue 10 e00051-19 jvi.asm.org 16
 o
n
 M
ay 30, 2019 by guest
http://jvi.asm.org/
D
ow
nloaded from
 
washed three times in TBS-T before incubation with secondary antibodies for 1.5 h. Secondary antibodies
were goat anti-rabbit IRDye 800CW (926-68032211; LiCOR) and goat anti-mouse IRDye 608LT (926-68020;
LiCOR); for immunoprecipitated samples, biotin-anti-mouse light chain followed by streptavidin IRDye
680LT (926-68031; LiCOR) was used. Finally, membranes were washed three times in TBS-T, dried, and
imaged using the LiCOR system and Odyssey software. Densitometry was calculated using ImageJ.
Intradermal mouse model of infection and intranasal challenge experiments. Female C57BL/6
mice 6 to 8 weeks old (n 5) were infected with 5 103 PFU in both ear pinnae with VACV strains vA55,
vΔA55, and vΔA55Rev that had been puriﬁed by sucrose density gradient centrifugation. Lesion size was
measured daily with a micrometer until day 21. At day 28 p.i. mice were infected intranasally with 107
PFU of VACV, and their weights were measured daily for 7 days.
Isolation of cell populations and staining for ﬂow cytometry. Cells from spleen and lymph nodes
were isolated by grinding the organ through a 40-m-pore-size nylon cell strainer to create single-cell
suspensions. Splenocytes were treated with red blood cell (RBC) lysis buffer to remove contaminating
RBCs. Single-cell suspensions were stained with ﬂuorescently labeled antibodies: CD3 (clone 145-2C11),
CD4 (GK1.5), CD8 (5H10-1), CD45R (RA-6B2), NK1.1 (PK136), CD69 (H1.2F3), F4/80 (BM8), Ly6G (1A8),
and CD16/32 (2.4G2) (purchased from BD Biosciences or BioLegend). These antibodies were puriﬁed or
conjugated with peridinin chlorophyll protein (PerCP)/Cy5.5, ﬂuorescein isothiocyanate (FITC), allophy-
cocyanin (APC)/Cy7, APC, phycoerythrin (PE)-Cy7, PE, or BV650. Isotype controls were used as negative
controls. Live cells were discriminated with a ﬁxable Live/Dead stain (Life Technologies). Stained cells
were analyzed by ﬂow cytometry on a BD LSR Fortessa (BD Biosciences), and data were analyzed with
FlowJo software (Tree Star, Inc.).
DimerX assay to detect VACV-speciﬁc CD8 T cells. A DimerX assay was performed according to
the manufacturer’s instructions (BD Biosciences) using H-2Kb–Ig fusion proteins and B820 peptide
(TSYKFESV), as described previously (37).
CD8 T-cell and NK cell killing assay. Cytotoxic T lymphocyte activity was assayed by 51Cr release
assay as described previously (37). VACV-infected EL4 cells or P815 cells were used as targets for
VACV-speciﬁc cytotoxic T-lymphocyte cell lysis or VACV-speciﬁc natural killer (NK) cell cytotoxicity,
respectively.
Statistics. All experiments were carried out in triplicate and are representative or an average of at
least three independent experiments unless otherwise stated. Data are the means standard deviations
(SD) or, for in vivo data,  standard errors of the means (SEM). All assays were analyzed by unpaired t
test with GraphPad Prism, version 6, software.
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